MX2023001335A - Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma. - Google Patents

Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma.

Info

Publication number
MX2023001335A
MX2023001335A MX2023001335A MX2023001335A MX2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A MX 2023001335 A MX2023001335 A MX 2023001335A
Authority
MX
Mexico
Prior art keywords
bcl
inhibitor
combination
pharmaceutical compositions
hypomethylating agent
Prior art date
Application number
MX2023001335A
Other languages
English (en)
Spanish (es)
Inventor
Emmelyne Dessein
Lisa Mahnke
Michael Robert Cooper
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2023001335A publication Critical patent/MX2023001335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023001335A 2020-07-31 2021-07-30 Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma. MX2023001335A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
MX2023001335A true MX2023001335A (es) 2023-04-27

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001335A MX2023001335A (es) 2020-07-31 2021-07-30 Combinacion de un inhibidor de bcl-2 y un agente hipometilante para tratar canceres, usos y composiciones farmaceuticas de la misma.

Country Status (15)

Country Link
US (1) US20230270748A1 (enExample)
EP (1) EP4188387A1 (enExample)
JP (1) JP2023537290A (enExample)
KR (1) KR20230044452A (enExample)
CN (1) CN116390735A (enExample)
AU (1) AU2021316674A1 (enExample)
BR (1) BR112023001307A2 (enExample)
CA (1) CA3190276A1 (enExample)
CL (1) CL2023000242A1 (enExample)
CR (1) CR20230046A (enExample)
IL (1) IL300145A (enExample)
JO (1) JOP20230013A1 (enExample)
MX (1) MX2023001335A (enExample)
PH (1) PH12023550205A1 (enExample)
WO (1) WO2022023514A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) * 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
GEP20237494B (en) 2018-10-31 2023-04-10 Servier Lab Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
JOP20230013A1 (ar) 2023-01-18
CL2023000242A1 (es) 2023-11-10
CN116390735A (zh) 2023-07-04
JP2023537290A (ja) 2023-08-31
CA3190276A1 (en) 2022-02-03
BR112023001307A2 (pt) 2023-02-14
US20230270748A1 (en) 2023-08-31
PH12023550205A1 (en) 2024-06-24
AU2021316674A1 (en) 2023-03-02
EP4188387A1 (en) 2023-06-07
KR20230044452A (ko) 2023-04-04
IL300145A (en) 2023-03-01
CR20230046A (es) 2023-04-11
WO2022023514A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
Rybak et al. Ototoxicity: bioprotective mechanisms
Kuhlen et al. Molecular approaches to treating pediatric leukemias
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
SI1656122T1 (sl) Transdermalni farmacevtski pripravki s kombinacijami učinkovin za zdravljenje Parkinsonove bolezni
Cerchietti et al. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
PH12023550205A1 (en) Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
PH12021550878A1 (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
Hurtubise et al. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells
CO2023009176A2 (es) Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
IL285628A (en) A pharmaceutical preparation containing a flt3 inhibitor and a hypomethylating agent for the treatment of acute myeloid leukemia
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
ECSP003756A (es) Mezcla de linezoild y otros agentes antibacterianos
MY146091A (en) Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
Friedmann et al. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer
Davies et al. Antisense oligonucleotides in the treatment of non–small-cell lung cancer
Nielsen et al. Metastatic soft tissue sarcoma in adults: Prognosis and treatment options
UA92592C2 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent such as taxane for the treatment of cancer
EP1847244A4 (en) METABOLISM SYNDROME IMPROVING AGING AND MEDICINE, ADDITIVE, FUNCTIONAL FOOD AND ADDITIVE FOOD ADDITIVE
WO2024250014A8 (en) Combination therapies for the treatment of cd33-positive hematological malignancies harboring mutations
MX2020010261A (es) Composicion para prevenir o tratar cancer, que comprende un agente disruptor vascular y un compuesto de taxano.
TR200400812T3 (tr) KanserÁtedavisiÁiçinÁretinoidÁreseptörÁligandlarınınÁveÁseçilenÁsitotoksikÁmaddelerinÁsinerjistikÁkombinasyonları
UA90658C2 (ru) Композиция антагониста vegf и антипролиферативного средства